Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have been given an average recommendation of “Hold” by the nine ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $6.75.

A number of equities research analysts have issued reports on the company. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday, May 22nd. Guggenheim upped their price target on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, April 10th. Mizuho started coverage on Zentalis Pharmaceuticals in a research note on Friday, July 17th. They issued an “outperform” rating and a $8.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Monday, July 6th. Finally, Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 31st.

Zentalis Pharmaceuticals Price Performance

Shares of Zentalis Pharmaceuticals stock opened at $4.33 on Wednesday. The company has a market cap of $308.25 million, a price-to-earnings ratio of -2.50 and a beta of 1.92. The company’s 50 day moving average is $4.15 and its 200 day moving average is $3.48. Zentalis Pharmaceuticals has a twelve month low of $1.21 and a twelve month high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.01). Sell-side analysts expect that Zentalis Pharmaceuticals will post -1.83 EPS for the current fiscal year.

Institutional Trading of Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. CTC Alternative Strategies Ltd. acquired a new stake in shares of Zentalis Pharmaceuticals in the first quarter valued at about $29,000. Invesco Ltd. boosted its holdings in Zentalis Pharmaceuticals by 8.6% during the 4th quarter. Invesco Ltd. now owns 188,582 shares of the company’s stock valued at $255,000 after acquiring an additional 14,961 shares during the period. Barr E S & Co. grew its holdings in shares of Zentalis Pharmaceuticals by 43.8% in the fourth quarter. Barr E S & Co. now owns 57,500 shares of the company’s stock valued at $78,000 after purchasing an additional 17,500 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Zentalis Pharmaceuticals by 0.7% in the third quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock valued at $4,386,000 after acquiring an additional 19,768 shares in the last quarter. Finally, Sivia Capital Partners LLC purchased a new stake in shares of Zentalis Pharmaceuticals during the fourth quarter worth approximately $27,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.